- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07501325
IgE específica de tropomiosina y hemocianina recombinantes en niños con sospecha de alergia al camarón
Valor Diagnóstico de la IgE Específica de la Tropomiosina Recombinante y la Hemocianina para el Diagnóstico de la Alergia a los Camarones Mediado por IgE en Niños en Vietnam
This study will evaluate whether blood tests that measure IgE antibodies to two shrimp proteins, tropomyosin and hemocyanin, can help diagnose shrimp allergy in children. Children with suspected IgE-mediated shrimp allergy will undergo oral food challenge, skin prick testing, and blood sampling. Oral food challenge results will be used as the reference standard to determine whether these tests can accurately identify true shrimp allergy and help improve diagnosis in clinical practice.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Shrimp allergy is an important cause of IgE-mediated food allergy in children, and diagnosis remains challenging because conventional tests may not reliably distinguish true clinical allergy from sensitization or cross-reactivity. Oral food challenge (OFC) remains the reference standard, but it is time-consuming, resource-intensive, and may trigger significant allergic reactions.
This interventional diagnostic study will enroll children with suspected IgE-mediated shrimp allergy. Participants will undergo OFC according to the study protocol, together with skin prick testing and blood sampling for measurement of specific IgE to recombinant tropomyosin and hemocyanin. To standardize the diagnostic procedure, OFC will be performed using black tiger shrimp (Penaeus monodon) in all participants. Additional OFCs using other shrimp species may be performed when the clinical history suggests reactions to a different shrimp species. OFC results will be used to classify participants as shrimp allergic or shrimp tolerant.
The study will estimate the proportion of true shrimp allergy among children with suspected shrimp allergy and evaluate the diagnostic performance of recombinant tropomyosin- and hemocyanin-specific IgE, alone and in combination with clinical history and skin prick test results. The findings are expected to support more accurate molecular diagnosis of shrimp allergy in children and help optimize the indication for OFC in clinical practice in Vietnam.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Ngoc Thi Nguyen, MD
- Número de teléfono: +84 908 876 976
- Correo electrónico: ntngoc.ncs25@ump.edu.vn
Ubicaciones de estudio
-
-
-
Ho Chi Minh City, Vietnam
- Reclutamiento
- Children's Hospital 1
-
Contacto:
- Ngoc Thi Nguyen, MD
- Número de teléfono: +84 908 876 976
- Correo electrónico: ntngoc.ncs25@ump.edu.vn
-
Investigador principal:
- Ngoc Thi Nguyen, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Children aged 1 to 16 years.
- Evaluated at the Allergy Unit of Children's Hospital 1.
- Clinical history suggestive of IgE-mediated shrimp allergy based on EAACI 2023 criteria, including at least 1 typical allergic symptom (urticaria, angioedema, vomiting, abdominal pain, diarrhea, cough, wheezing, dyspnea, or hypotension), symptom onset within 2 hours after shrimp ingestion, and recurrence on at least 2 separate exposures.
- Parent or legal guardian able to provide written informed consent; child assent obtained when appropriate.
Exclusion Criteria:
- Acute illness at the time of enrollment or challenge, including acute respiratory infection, acute gastrointestinal infection, or acute asthma exacerbation.
- Severe chronic disease, including malignancy, severe liver or kidney disease, primary immunodeficiency, or significant heart disease affecting hemodynamic status.
- Mental or behavioral disorder that prevents completion of study procedures.
- Use of immunosuppressive medication (oral corticosteroids, cytotoxic drugs, or biologic agents) within 4 weeks before enrollment, or intravenous immunoglobulin within the previous 3 months.
Exclusion Criteria:
- Acute illness at the time of enrollment or challenge, including acute respiratory infection, acute gastrointestinal infection, or acute asthma exacerbation; participants may be rescheduled after recovery.
- Severe chronic disease, including malignancy, severe liver or kidney disease, primary immunodeficiency, or significant heart disease affecting hemodynamic status.
- Mental or behavioral disorder that prevents completion of study procedures.
- Use of immunosuppressive medication (oral corticosteroids, cytotoxic drugs, or biologic agents) within 4 weeks before enrollment, or intravenous immunoglobulin within the previous 3 months.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Diagnóstico
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Children With Suspected IgE-Mediated Shrimp Allergy
Children with suspected IgE-mediated shrimp allergy who undergo the study procedures, including oral food challenge, skin prick testing, and blood sampling for measurement of recombinant tropomyosin- and hemocyanin-specific IgE. Oral food challenge will be standardized using black tiger shrimp (Penaeus monodon), with additional challenge using other shrimp species when clinically indicated. |
Oral food challenge with shrimp performed according to the study protocol to confirm or exclude IgE-mediated shrimp allergy in children with suspected shrimp allergy. To standardize the challenge material, black tiger shrimp (Penaeus monodon) will be used in all participants. Additional oral food challenges using other shrimp species may be performed when the clinical history suggests reactions to a different shrimp species. The oral food challenge result serves as the reference standard for diagnostic evaluation in this study. Skin prick testing performed as part of the diagnostic evaluation in children with suspected IgE-mediated shrimp allergy. Blood testing to measure specific IgE to recombinant tropomyosin and hemocyanin as part of the diagnostic evaluation of suspected shrimp allergy. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Oral Food Challenge-Confirmed IgE-Mediated Shrimp Allergy
Periodo de tiempo: At the time of the oral food challenge during the baseline diagnostic evaluation
|
Participants will be classified as having true IgE-mediated shrimp allergy if the oral food challenge is positive according to the study protocol. A negative oral food challenge indicates shrimp tolerance. Oral food challenge results will be used as the reference standard for subsequent diagnostic performance analyses. |
At the time of the oral food challenge during the baseline diagnostic evaluation
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Diagnostic Accuracy of Recombinant Tropomyosin-Specific IgE for Oral Food Challenge-Confirmed Shrimp Allergy
Periodo de tiempo: During the baseline diagnostic evaluation
|
Diagnostic performance of recombinant tropomyosin-specific IgE will be evaluated against oral food challenge results, including receiver operating characteristic analysis, area under the curve, optimal cutoff, sensitivity, specificity, positive predictive value, and negative predictive value. |
During the baseline diagnostic evaluation
|
|
Diagnostic Accuracy of Recombinant Hemocyanin-Specific IgE for Oral Food Challenge-Confirmed Shrimp Allergy
Periodo de tiempo: During the baseline diagnostic evaluation
|
Diagnostic performance of recombinant hemocyanin-specific IgE will be evaluated against oral food challenge results, including receiver operating characteristic analysis, area under the curve, optimal cutoff, sensitivity, specificity, positive predictive value, and negative predictive value. |
During the baseline diagnostic evaluation
|
|
Diagnostic Accuracy of a Combined Model Incorporating Recombinant Tropomyosin-Specific IgE, Recombinant Hemocyanin-Specific IgE, Clinical History, and Skin Prick Test
Periodo de tiempo: During the baseline diagnostic evaluation
|
A combined diagnostic model using recombinant tropomyosin-specific IgE, recombinant hemocyanin-specific IgE, clinical history suggestive of shrimp allergy, and skin prick test results will be evaluated against oral food challenge results. Model performance will include receiver operating characteristic analysis and area under the curve. |
During the baseline diagnostic evaluation
|
Colaboradores e Investigadores
Colaboradores
Investigadores
- Investigador principal: Tu HK Trinh, MD, PhD, University of Medicine and Pharmacy at Ho Chi Minh City
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del sistema inmunológico
- Hipersensibilidad, Inmediata
- Hipersensibilidad
- Hipersensibilidad a los mariscos
- Hipersensibilidad alimentaria
- Técnicas de investigación
- Técnicas de laboratorio clínico
- Técnicas y procedimientos de diagnóstico
- Diagnóstico
- Técnicas inmunológicas
- Pruebas inmunológicas
- Pruebas de piel
- Pruebas de parche
Otros números de identificación del estudio
- UMP-SHRIMP-IgE-2025
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .